Biomarkers, imaging and safety in resmetirom 52 week non-cirrhotic NASH phase 3 clinical trial, completed open-label arm of maestro-NAFLD-1
Harrison, Dr. S.A., Mangia, Dr. A., Lasierra-Resa, Dr. P., Cubberley, Ms. S., Taub, Dr. R.A., Neff, Dr. G.W., Alkhouri, Dr. Naim, Bashir, Dr. Mustafa
Published in Digestive and liver disease (01.03.2022)
Published in Digestive and liver disease (01.03.2022)
Get full text
Journal Article